Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HB0025 + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Huabo Biopharm Co., Ltd.
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
HB0025 + nab-paclitaxel is a combination therapy under clinical investigation for the treatment of triple-negative breast cancer (TNBC). HB0025, also known as sotiburafusp alfa, is a bispecific antibody developed by Huabo Biopharm that targets both Programmed Death-Ligand 1 (PD-L1) and Vascular Endothelial Growth Factor (VEGF). It functions by combining an anti-PD-L1 monoclonal antibody with a VEGFR1 fragment that acts as a VEGF trap, thereby simultaneously inhibiting tumor-induced immunosuppression and angiogenesis. Nab-paclitaxel is an albumin-bound formulation of paclitaxel, a microtubule-stabilizing agent that inhibits mitosis. This combination is being evaluated in Phase II trials as a first-line therapy for patients with unresectable, locally advanced, or metastatic TNBC, aiming to leverage the synergistic effects of immune checkpoint inhibition, anti-angiogenesis, and cytotoxic chemotherapy.
- Brand names
- Abraxane
- Other names
- sotiburafusp alfa + nab-paclitaxelHB0025 + albumin-bound paclitaxel
02
Targets
SPARC (Secreted protein acidic and rich in cysteine)VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))gp60 (GP60 Receptor)
Beyond the preview
Go deeper on HB0025 + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HB0025 + nab-paclitaxel.